25 XP   0   0   10

NanJing Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse NanJing Pharmaceutical Co Ltd together

PenkeI guess you are interested in NanJing Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NanJing Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NanJing Pharmaceutical Co Ltd

I send you an email if I find something interesting about NanJing Pharmaceutical Co Ltd.

Quick analysis of NanJing Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of NanJing Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.07
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥5.39
Expected worth in 1 year
¥5.80
How sure are you?
97.5%

+ What do you gain per year?

Total Gains per Share
¥0.88
Return On Investment
19.7%

For what price can you sell your share?

Current Price per Share
¥4.48
Expected price per share
¥4.38 - ¥4.71
How sure are you?
50%

1. Valuation of NanJing Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥4.48

Intrinsic Value Per Share

¥-55.02 - ¥-65.84

Total Value Per Share

¥-49.63 - ¥-60.44

2. Growth of NanJing Pharmaceutical Co Ltd (5 min.)




Is NanJing Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$978m$848.9m$106.2m11.1%

How much money is NanJing Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$19.5m$21.7m-$2.1m-11.2%
Net Profit Margin1.1%1.3%--

How much money comes from the company's main activities?

3. Financial Health of NanJing Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of NanJing Pharmaceutical Co Ltd? (5 min.)

Welcome investor! NanJing Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of NanJing Pharmaceutical Co Ltd.

What can you expect buying and holding a share of NanJing Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of NanJing Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of NanJing Pharmaceutical Co Ltd is ¥4.48. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of NanJing Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in NanJing Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥5.39. Based on the TTM, the Book Value Change Per Share is ¥0.10 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.12 per quarter.
Based on historical numbers we can estimate the returns while holding a share of NanJing Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.3%0.010.3%0.020.4%0.010.3%0.010.2%
Usd Book Value Change Per Share0.010.3%0.010.3%0.040.9%0.010.3%0.020.3%
Usd Dividend Per Share0.010.2%0.020.4%0.030.6%0.020.3%0.020.4%
Usd Total Gains Per Share0.020.5%0.030.7%0.071.5%0.030.7%0.030.7%
Usd Price Per Share0.72-0.72-0.71-0.66-0.86-
Price to Earnings Ratio12.89-12.17-10.97-14.72-42.78-
Price-to-Total Gains Ratio31.75-26.35-16.24-24.76-39.27-
Price to Book Ratio0.96-0.99-1.10-1.19-2.68-
Price-to-Total Gains Ratio31.75-26.35-16.24-24.76-39.27-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.620032
Number of shares1612
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.02
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.030.03
Gains per Quarter (1612 shares)49.2848.66
Gains per Year (1612 shares)197.13194.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1106911879996185
2212182384198191380
3318274581297287575
4424365778396383770
5530456975495478965
663654711725945741160
774163813696936701355
884773015667927651550
995382117638918611745
10105991219609909571940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%78.00.09.089.7%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%18.02.00.090.0%34.06.00.085.0%66.021.00.075.9%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%70.00.017.080.5%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%39.01.00.097.5%83.04.00.095.4%

Fundamentals of NanJing Pharmaceutical Co Ltd

About NanJing Pharmaceutical Co Ltd

NanJing Pharmaceutical Company Limited engages in the pharmaceutical wholesale and retail businesses in China. It also operates various pharmacies and an e-commerce platform. The company was founded in 1951 and is based in Nanjing, China.

Fundamental data was last updated by Penke on 2024-03-26 19:33:09.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of NanJing Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit NanJing Pharmaceutical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 1.0% means that ¥0.01 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 1.0%. The company is not making a profit/loss.
  • The TTM is 1.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.1%-0.1%
TTM1.1%YOY1.3%-0.2%
TTM1.1%5Y1.0%+0.0%
5Y1.0%10Y0.9%+0.2%
1.1.2. Return on Assets

Shows how efficient NanJing Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • 0.4% Return on Assets means that NanJing Pharmaceutical Co Ltd generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.4%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.4%TTM0.4%0.0%
TTM0.4%YOY0.6%-0.1%
TTM0.4%5Y0.4%0.0%
5Y0.4%10Y0.4%+0.1%
1.1.3. Return on Equity

Shows how efficient NanJing Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • 2.1% Return on Equity means NanJing Pharmaceutical Co Ltd generated ¥0.02 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 2.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.1%TTM2.3%-0.2%
TTM2.3%YOY2.9%-0.6%
TTM2.3%5Y2.4%-0.1%
5Y2.4%10Y2.2%+0.2%

1.2. Operating Efficiency of NanJing Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient NanJing Pharmaceutical Co Ltd is operating .

  • Measures how much profit NanJing Pharmaceutical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.1%-2.1%
TTM2.1%YOY2.9%-0.8%
TTM2.1%5Y2.6%-0.5%
5Y2.6%10Y1.4%+1.2%
1.2.2. Operating Ratio

Measures how efficient NanJing Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.91 means that the operating costs are ¥1.91 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 1.909. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.907. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.909TTM1.907+0.001
TTM1.907YOY1.907+0.001
TTM1.9075Y1.907+0.000
5Y1.90710Y1.470+0.437

1.3. Liquidity of NanJing Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if NanJing Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.31 means the company has ¥1.31 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 1.308. The company is just able to pay all its short-term debts.
  • The TTM is 1.326. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.308TTM1.326-0.018
TTM1.326YOY1.303+0.023
TTM1.3265Y1.251+0.075
5Y1.25110Y0.685+0.566
1.3.2. Quick Ratio

Measures if NanJing Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.72 means the company can pay off ¥0.72 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 0.715. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.806. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.715TTM0.806-0.091
TTM0.806YOY0.894-0.087
TTM0.8065Y0.811-0.005
5Y0.81110Y0.774+0.037

1.4. Solvency of NanJing Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of NanJing Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare NanJing Pharmaceutical Co Ltd to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.79 means that NanJing Pharmaceutical Co Ltd assets are financed with 78.7% credit (debt) and the remaining percentage (100% - 78.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 0.787. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.789. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.787TTM0.789-0.002
TTM0.789YOY0.783+0.007
TTM0.7895Y0.796-0.006
5Y0.79610Y0.802-0.006
1.4.2. Debt to Equity Ratio

Measures if NanJing Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 415.4% means that company has ¥4.15 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The MRQ is 4.154. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.203. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.154TTM4.203-0.049
TTM4.203YOY4.052+0.150
TTM4.2035Y4.406-0.203
5Y4.40610Y4.849-0.443

2. Market Valuation of NanJing Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings NanJing Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare NanJing Pharmaceutical Co Ltd to the Drug Manufacturers - General industry mean.
  • A PE ratio of 12.89 means the investor is paying ¥12.89 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The EOD is 11.146. Based on the earnings, the company is underpriced. +1
  • The MRQ is 12.888. Based on the earnings, the company is underpriced. +1
  • The TTM is 12.166. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD11.146MRQ12.888-1.742
MRQ12.888TTM12.166+0.722
TTM12.166YOY10.969+1.197
TTM12.1665Y14.717-2.551
5Y14.71710Y42.782-28.064
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The EOD is -0.811. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.937. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.425. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-0.811MRQ-0.937+0.127
MRQ-0.937TTM0.425-1.362
TTM0.425YOY-1.262+1.687
TTM0.4255Y2.959-2.534
5Y2.95910Y-0.395+3.355
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of NanJing Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 0.96 means the investor is paying ¥0.96 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of NanJing Pharmaceutical Co Ltd:

  • The EOD is 0.831. Based on the equity, the company is cheap. +2
  • The MRQ is 0.960. Based on the equity, the company is cheap. +2
  • The TTM is 0.990. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.831MRQ0.960-0.130
MRQ0.960TTM0.990-0.029
TTM0.990YOY1.095-0.106
TTM0.9905Y1.192-0.202
5Y1.19210Y2.682-1.490
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of NanJing Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0950.102-7%0.287-67%0.107-11%0.109-13%
Book Value Per Share--5.3935.267+2%4.682+15%4.093+32%3.088+75%
Current Ratio--1.3081.326-1%1.303+0%1.251+5%0.685+91%
Debt To Asset Ratio--0.7870.7890%0.783+1%0.796-1%0.802-2%
Debt To Equity Ratio--4.1544.203-1%4.052+3%4.406-6%4.849-14%
Dividend Per Share--0.0680.119-43%0.193-65%0.111-39%0.117-42%
Eps--0.1000.108-7%0.120-16%0.089+13%0.062+62%
Free Cash Flow Per Share---1.382-0.397-71%-0.142-90%-0.190-86%-0.154-89%
Free Cash Flow To Equity Per Share---1.382-0.831-40%0.047-3062%-0.062-96%-0.032-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---65.837--------
Intrinsic Value_10Y_min---55.019--------
Intrinsic Value_1Y_max---1.845--------
Intrinsic Value_1Y_min---1.810--------
Intrinsic Value_3Y_max---9.166--------
Intrinsic Value_3Y_min---8.677--------
Intrinsic Value_5Y_max---20.852--------
Intrinsic Value_5Y_min---19.043--------
Market Cap5869830471.680-16%6786996642.1606829908220.050-1%6675621931.520+2%6243967993.578+9%8127390215.413-16%
Net Profit Margin--0.0100.011-6%0.013-22%0.010-4%0.009+15%
Operating Margin---0.021-100%0.029-100%0.026-100%0.014-100%
Operating Ratio--1.9091.907+0%1.907+0%1.907+0%1.470+30%
Pb Ratio0.831-16%0.9600.990-3%1.095-12%1.192-19%2.682-64%
Pe Ratio11.146-16%12.88812.166+6%10.969+17%14.717-12%42.782-70%
Price Per Share4.480-16%5.1805.213-1%5.095+2%4.766+9%6.203-16%
Price To Free Cash Flow Ratio-0.811+14%-0.9370.425-320%-1.262+35%2.959-132%-0.395-58%
Price To Total Gains Ratio27.459-16%31.74926.353+20%16.244+95%24.758+28%39.267-19%
Quick Ratio--0.7150.806-11%0.894-20%0.811-12%0.774-8%
Return On Assets--0.0040.004-8%0.006-29%0.004-10%0.004+4%
Return On Equity--0.0210.023-9%0.029-28%0.024-14%0.022-4%
Total Gains Per Share--0.1630.221-26%0.480-66%0.218-25%0.226-28%
Usd Book Value--978005517.522955199642.404+2%848959968.619+15%742265509.632+32%560000709.903+75%
Usd Book Value Change Per Share--0.0130.014-7%0.040-67%0.015-11%0.015-13%
Usd Book Value Per Share--0.7460.729+2%0.648+15%0.567+32%0.427+75%
Usd Dividend Per Share--0.0090.016-43%0.027-65%0.015-39%0.016-42%
Usd Eps--0.0140.015-7%0.017-16%0.012+13%0.009+62%
Usd Free Cash Flow---250545410.340-71961556.730-71%-25740045.892-90%-34374485.977-86%-17498153.042-93%
Usd Free Cash Flow Per Share---0.191-0.055-71%-0.020-90%-0.026-86%-0.021-89%
Usd Free Cash Flow To Equity Per Share---0.191-0.115-40%0.006-3062%-0.009-96%-0.004-98%
Usd Market Cap812384537.281-16%939320335.275945259297.655-1%923906075.322+2%864165170.311+9%1124830805.813-16%
Usd Price Per Share0.620-16%0.7170.721-1%0.705+2%0.660+9%0.858-16%
Usd Profit--18220844.87719574047.715-7%21766687.520-16%16132531.559+13%11251996.701+62%
Usd Revenue--1827386283.5531845293290.535-1%1701023797.071+7%1533278198.329+19%1211037429.772+51%
Usd Total Gains Per Share--0.0230.031-26%0.066-66%0.030-25%0.031-28%
 EOD+3 -5MRQTTM+9 -26YOY+10 -255Y+17 -1810Y+16 -19

3.2. Fundamental Score

Let's check the fundamental score of NanJing Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1511.146
Price to Book Ratio (EOD)Between0-10.831
Net Profit Margin (MRQ)Greater than00.010
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.715
Current Ratio (MRQ)Greater than11.308
Debt to Asset Ratio (MRQ)Less than10.787
Debt to Equity Ratio (MRQ)Less than14.154
Return on Equity (MRQ)Greater than0.150.021
Return on Assets (MRQ)Greater than0.050.004
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of NanJing Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.245
Ma 20Greater thanMa 504.512
Ma 50Greater thanMa 1004.488
Ma 100Greater thanMa 2004.759
OpenGreater thanClose4.440
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Interest Income  3,91218,18122,093-18,2423,8514,9338,784-21,927-13,143



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets33,202,829
Total Liabilities26,136,315
Total Stockholder Equity6,291,890
 As reported
Total Liabilities 26,136,315
Total Stockholder Equity+ 6,291,890
Total Assets = 33,202,829

Assets

Total Assets33,202,829
Total Current Assets30,812,013
Long-term Assets2,390,816
Total Current Assets
Cash And Cash Equivalents 1,182,315
Net Receivables 16,845,619
Inventory 5,696,643
Other Current Assets 121,820
Total Current Assets  (as reported)30,812,013
Total Current Assets  (calculated)23,846,396
+/- 6,965,617
Long-term Assets
Property Plant Equipment 1,498,219
Goodwill 72,167
Intangible Assets 218,130
Long-term Assets Other 4,978
Long-term Assets  (as reported)2,390,816
Long-term Assets  (calculated)1,793,493
+/- 597,322

Liabilities & Shareholders' Equity

Total Current Liabilities23,557,817
Long-term Liabilities2,578,498
Total Stockholder Equity6,291,890
Total Current Liabilities
Short Long Term Debt 3,696,195
Accounts payable 9,523,195
Other Current Liabilities 4,670,963
Total Current Liabilities  (as reported)23,557,817
Total Current Liabilities  (calculated)17,890,352
+/- 5,667,465
Long-term Liabilities
Long term Debt 2,109,765
Capital Lease Obligations Min Short Term Debt121,694
Long-term Liabilities  (as reported)2,578,498
Long-term Liabilities  (calculated)2,231,459
+/- 347,039
Total Stockholder Equity
Retained Earnings 2,236,576
Total Stockholder Equity (as reported)6,291,890
Total Stockholder Equity (calculated)2,236,576
+/- 4,055,314
Other
Capital Stock1,310,231
Common Stock Shares Outstanding 1,310,231
Net Debt 4,623,645
Net Invested Capital 12,097,850
Net Working Capital 7,254,196
Property Plant and Equipment Gross 1,498,219



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-06-302000-12-312000-06-30
> Total Assets 
1,210,604
1,229,238
1,236,641
1,169,969
1,329,047
1,366,946
1,436,392
1,816,297
1,907,926
2,411,173
2,477,764
2,629,994
1,577,371
2,835,281
2,922,649
3,134,129
3,231,737
3,289,375
3,416,426
3,328,739
3,549,141
3,547,881
3,614,703
3,687,228
4,006,421
4,791,953
4,908,896
4,999,293
5,163,465
5,304,167
5,405,154
5,043,950
5,596,532
6,355,118
6,134,129
6,517,671
6,965,596
7,558,084
7,728,096
8,373,920
9,398,615
9,436,379
9,315,077
9,024,539
9,837,058
10,369,427
10,567,567
9,227,049
9,536,112
9,480,090
10,319,836
9,649,666
10,476,843
10,271,078
11,258,727
11,362,292
12,008,623
12,514,420
13,212,678
12,594,788
13,709,088
13,462,229
14,922,445
13,961,834
15,031,566
14,735,279
16,364,623
15,925,206
18,066,990
18,039,891
19,395,963
19,554,816
22,083,634
22,024,258
23,805,430
21,965,560
24,266,271
21,450,298
22,867,376
23,409,572
25,691,053
25,450,824
26,839,656
25,885,712
28,097,313
27,739,470
31,114,446
31,650,960
32,857,680
33,371,894
33,202,829
33,202,82933,371,89432,857,68031,650,96031,114,44627,739,47028,097,31325,885,71226,839,65625,450,82425,691,05323,409,57222,867,37621,450,29824,266,27121,965,56023,805,43022,024,25822,083,63419,554,81619,395,96318,039,89118,066,99015,925,20616,364,62314,735,27915,031,56613,961,83414,922,44513,462,22913,709,08812,594,78813,212,67812,514,42012,008,62311,362,29211,258,72710,271,07810,476,8439,649,66610,319,8369,480,0909,536,1129,227,04910,567,56710,369,4279,837,0589,024,5399,315,0779,436,3799,398,6158,373,9207,728,0967,558,0846,965,5966,517,6716,134,1296,355,1185,596,5325,043,9505,405,1545,304,1675,163,4654,999,2934,908,8964,791,9534,006,4213,687,2283,614,7033,547,8813,549,1413,328,7393,416,4263,289,3753,231,7373,134,1292,922,6492,835,2811,577,3712,629,9942,477,7642,411,1731,907,9261,816,2971,436,3921,366,9461,329,0471,169,9691,236,6411,229,2381,210,604
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,342,641
17,683,753
17,700,793
20,115,419
20,001,264
21,843,042
19,747,772
22,029,694
19,232,970
20,653,931
21,164,734
23,272,221
23,004,540
24,378,858
23,457,942
25,682,263
25,320,723
28,692,875
29,261,483
30,450,054
30,989,186
30,812,013
30,812,01330,989,18630,450,05429,261,48328,692,87525,320,72325,682,26323,457,94224,378,85823,004,54023,272,22121,164,73420,653,93119,232,97022,029,69419,747,77221,843,04220,001,26420,115,41917,700,79317,683,75316,342,641000000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,079,922
1,623,486
2,265,008
2,504,651
1,950,886
2,376,938
2,103,416
3,356,677
1,032,272
1,074,986
1,478,749
1,775,785
1,023,897
1,043,097
2,093,321
2,037,063
1,534,337
1,496,214
2,327,196
1,387,527
2,007,310
1,182,315
1,182,3152,007,3101,387,5272,327,1961,496,2141,534,3372,037,0632,093,3211,043,0971,023,8971,775,7851,478,7491,074,9861,032,2723,356,6772,103,4162,376,9381,950,8862,504,6512,265,0081,623,4862,079,922000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
340,363
286,380
362,926
313,516
403,717
433,060
484,321
510,318
609,942
817,875
948,080
943,963
11,872
1,124,087
1,130,915
1,204,038
1,322,278
1,368,814
1,466,314
1,182,352
1,397,704
1,425,490
1,541,302
1,378,253
1,757,829
2,011,928
1,872,362
1,913,589
2,162,089
2,121,941
2,313,396
1,975,897
2,124,080
2,552,446
2,467,890
2,308,348
2,754,007
3,002,748
3,337,310
3,121,174
3,763,482
3,878,935
3,945,284
4,160,320
4,613,168
4,743,153
5,295,428
3,998,244
4,932,859
5,121,965
5,617,615
4,740,958
5,856,401
5,718,303
6,628,587
5,974,345
6,789,974
7,401,899
8,131,596
7,328,309
8,295,774
8,050,476
8,836,491
7,803,361
8,769,594
8,982,162
10,134,961
8,923,270
10,798,798
10,823,838
12,284,414
11,496,293
10,433,267
10,574,883
11,523,298
12,759,465
13,482,028
13,691,573
14,826,499
14,617,168
16,039,919
16,506,986
18,151,221
15,274,246
17,192,399
17,500,230
21,104,265
19,333,513
16,164,568
21,395,714
16,845,619
16,845,61921,395,71416,164,56819,333,51321,104,26517,500,23017,192,39915,274,24618,151,22116,506,98616,039,91914,617,16814,826,49913,691,57313,482,02812,759,46511,523,29810,574,88310,433,26711,496,29312,284,41410,823,83810,798,7988,923,27010,134,9618,982,1628,769,5947,803,3618,836,4918,050,4768,295,7747,328,3098,131,5967,401,8996,789,9745,974,3456,628,5875,718,3035,856,4014,740,9585,617,6155,121,9654,932,8593,998,2445,295,4284,743,1534,613,1684,160,3203,945,2843,878,9353,763,4823,121,1743,337,3103,002,7482,754,0072,308,3482,467,8902,552,4462,124,0801,975,8972,313,3962,121,9412,162,0891,913,5891,872,3622,011,9281,757,8291,378,2531,541,3021,425,4901,397,7041,182,3521,466,3141,368,8141,322,2781,204,0381,130,9151,124,08711,872943,963948,080817,875609,942510,318484,321433,060403,717313,516362,926286,380340,363
       Other Current Assets 
18,705
27,130
24,035
28,813
30,851
35,241
33,323
44,290
34,725
40,843
38,614
65,749
49,589
56,608
62,724
151,840
123,244
132,996
128,818
189,795
143,352
142,073
144,098
189,727
157,031
227,689
195,818
274,325
201,343
268,723
272,098
362,114
361,093
369,805
373,635
549,130
575,953
420,143
452,573
673,125
588,532
552,088
534,078
472,025
340,970
686,856
791,034
528,615
535,233
402,737
413,752
544,033
501,772
487,418
365,475
505,120
478,293
453,204
502,908
601,390
543,607
508,773
483,827
842,731
635,011
667,376
608,497
1,001,942
658,317
630,667
580,600
997,637
110,161
71,061
93,711
1,167,299
821,209
658,063
693,246
1,003,330
805,177
817,360
675,857
1,570,975
1,159,174
1,365,438
947,391
1,812,515
211,360
1,599,308
121,820
121,8201,599,308211,3601,812,515947,3911,365,4381,159,1741,570,975675,857817,360805,1771,003,330693,246658,063821,2091,167,29993,71171,061110,161997,637580,600630,667658,3171,001,942608,497667,376635,011842,731483,827508,773543,607601,390502,908453,204478,293505,120365,475487,418501,772544,033413,752402,737535,233528,615791,034686,856340,970472,025534,078552,088588,532673,125452,573420,143575,953549,130373,635369,805361,093362,114272,098268,723201,343274,325195,818227,689157,031189,727144,098142,073143,352189,795128,818132,996123,244151,84062,72456,60849,58965,74938,61440,84334,72544,29033,32335,24130,85128,81324,03527,13018,705
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,968,214
2,022,994
1,962,387
2,217,788
2,236,577
2,217,328
2,213,445
2,244,838
2,418,832
2,446,284
2,460,799
2,427,770
2,415,050
2,418,748
2,421,571
2,389,477
2,407,626
2,382,708
2,390,816
2,390,8162,382,7082,407,6262,389,4772,421,5712,418,7482,415,0502,427,7702,460,7992,446,2842,418,8322,244,8382,213,4452,217,3282,236,5772,217,7881,962,3872,022,9941,968,214000000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
377,894
398,304
376,048
382,652
394,038
393,909
398,780
410,049
408,098
537,560
535,417
529,676
540,814
538,462
553,565
542,782
535,585
637,525
535,228
652,991
546,354
648,700
528,402
630,679
430,658
708,278
491,415
709,264
495,325
679,136
442,741
673,430
469,506
765,199
539,393
946,966
675,744
1,020,374
731,056
1,054,024
824,294
1,148,323
889,636
928,462
591,024
1,080,439
697,370
985,350
585,610
964,280
633,604
953,226
670,663
660,412
669,431
620,698
633,953
633,743
635,826
650,604
663,043
739,076
769,343
807,407
795,236
797,803
824,398
872,993
896,044
920,620
965,014
1,094,013
1,087,536
1,167,590
1,182,075
1,177,998
1,151,767
1,174,859
1,168,583
1,186,769
1,602,279
1,470,899
1,495,137
1,492,048
1,543,711
1,523,820
1,548,026
1,519,069
1,516,350
1,510,577
1,498,219
1,498,2191,510,5771,516,3501,519,0691,548,0261,523,8201,543,7111,492,0481,495,1371,470,8991,602,2791,186,7691,168,5831,174,8591,151,7671,177,9981,182,0751,167,5901,087,5361,094,013965,014920,620896,044872,993824,398797,803795,236807,407769,343739,076663,043650,604635,826633,743633,953620,698669,431660,412670,663953,226633,604964,280585,610985,350697,3701,080,439591,024928,462889,6361,148,323824,2941,054,024731,0561,020,374675,744946,966539,393765,199469,506673,430442,741679,136495,325709,264491,415708,278430,658630,679528,402648,700546,354652,991535,228637,525535,585542,782553,565538,462540,814529,676535,417537,560408,098410,049398,780393,909394,038382,652376,048398,304377,894
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,368
3,368
3,368
3,368
3,073
3,073
3,073
3,073
3,073
3,073
3,073
2,382
2,382
2,382
2,382
2,382
2,382
2,382
13,630
13,525
13,525
39,467
39,467
74,167
74,167
74,167
74,167
74,167
74,167
74,167
74,167
72,167
72,167
72,167
72,167
72,167
72,167
72,167
72,167
72,16772,16772,16772,16772,16772,16772,16772,16774,16774,16774,16774,16774,16774,16774,16774,16739,46739,46713,52513,52513,6302,3822,3822,3822,3822,3822,3822,3823,0733,0733,0733,0733,0733,0733,0733,3683,3683,3683,3680000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
280,732
246,062
231,677
350,917
265,122
264,789
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000264,789265,122350,917231,677246,062280,732000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
12,071
14,358
20,705
16,297
36,868
36,248
38,055
53,595
53,123
79,521
79,759
91,307
92,823
91,817
91,004
116,590
115,687
12,350
111,991
16,583
123,528
15,379
129,726
15,521
135,102
13,776
228,095
13,422
230,673
12,396
230,103
11,331
228,010
10,460
287,076
32,739
353,472
31,665
339,901
16,580
351,773
16,136
360,880
33,598
437,560
37,031
439,363
51,855
414,286
46,007
402,649
38,657
381,407
375,682
370,798
197,254
192,475
185,977
192,843
183,255
199,919
195,506
190,890
192,748
200,022
194,054
193,198
193,303
188,213
185,399
186,877
191,644
191,116
29,624
192,123
255,446
249,736
245,180
247,487
282,168
96,914
276,105
273,725
268,112
261,195
259,660
255,549
245,284
231,169
227,120
218,130
218,130227,120231,169245,284255,549259,660261,195268,112273,725276,10596,914282,168247,487245,180249,736255,446192,12329,624191,116191,644186,877185,399188,213193,303193,198194,054200,022192,748190,890195,506199,919183,255192,843185,977192,475197,254370,798375,682381,40738,657402,64946,007414,28651,855439,36337,031437,56033,598360,88016,136351,77316,580339,90131,665353,47232,739287,07610,460228,01011,331230,10312,396230,67313,422228,09513,776135,10215,521129,72615,379123,52816,583111,99112,350115,687116,59091,00491,81792,82391,30779,75979,52153,12353,59538,05536,24836,86816,29720,70514,35812,071
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
2,022,994
1,962,387
11,034
2,236,577
0
1,168,583
32,350
29,310
30,122
33,736
36,849
7,679
4,252
2,073
2,050
1,672
3,193
4,978
4,9783,1931,6722,0502,0734,2527,67936,84933,73630,12229,31032,3501,168,58302,236,57711,0341,962,3872,022,99410,000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
723,385
742,308
750,931
697,926
840,633
876,958
939,456
1,311,005
1,385,276
1,818,898
1,881,169
2,018,159
1,983,423
2,206,976
2,305,994
2,519,991
2,610,122
2,652,645
2,761,879
2,681,803
2,895,465
2,904,976
2,975,568
3,043,259
3,342,705
4,100,165
4,226,290
4,298,366
4,459,307
4,634,173
4,775,622
4,433,259
4,969,783
5,685,161
5,457,387
5,772,895
6,213,985
6,267,305
6,427,332
7,110,014
8,089,028
8,095,697
7,985,426
7,666,412
8,471,157
9,029,535
9,173,172
7,913,360
8,215,519
8,127,401
8,977,257
8,361,623
9,194,477
8,997,732
9,965,389
8,924,967
9,505,772
9,954,820
10,601,806
9,908,200
10,961,746
10,704,062
12,103,060
10,892,509
11,887,651
11,571,268
13,260,748
12,738,684
13,879,161
13,826,263
15,138,177
15,445,679
17,899,674
17,791,478
19,440,720
17,445,574
19,636,750
16,839,528
18,122,715
18,589,442
20,766,015
20,497,812
21,812,898
20,651,949
21,731,597
21,333,387
24,583,595
24,956,074
25,954,079
26,429,969
26,136,315
26,136,31526,429,96925,954,07924,956,07424,583,59521,333,38721,731,59720,651,94921,812,89820,497,81220,766,01518,589,44218,122,71516,839,52819,636,75017,445,57419,440,72017,791,47817,899,67415,445,67915,138,17713,826,26313,879,16112,738,68413,260,74811,571,26811,887,65110,892,50912,103,06010,704,06210,961,7469,908,20010,601,8069,954,8209,505,7728,924,9679,965,3898,997,7329,194,4778,361,6238,977,2578,127,4018,215,5197,913,3609,173,1729,029,5358,471,1577,666,4127,985,4268,095,6978,089,0287,110,0146,427,3326,267,3056,213,9855,772,8955,457,3875,685,1614,969,7834,433,2594,775,6224,634,1734,459,3074,298,3664,226,2904,100,1653,342,7053,043,2592,975,5682,904,9762,895,4652,681,8032,761,8792,652,6452,610,1222,519,9912,305,9942,206,9761,983,4232,018,1591,881,1691,818,8981,385,2761,311,005939,456876,958840,633697,926750,931742,308723,385
   > Total Current Liabilities 
697,549
714,940
750,460
696,208
829,680
866,225
930,686
1,302,551
1,376,673
1,806,379
1,868,269
2,012,760
1,974,674
2,198,834
2,297,331
2,516,533
2,604,819
2,647,363
2,756,806
2,671,522
2,883,945
2,893,487
2,948,474
2,925,930
3,224,271
3,974,363
4,097,790
4,180,395
4,324,389
4,504,836
4,628,133
4,291,622
4,810,168
5,510,348
5,282,832
5,676,284
6,117,324
6,172,341
6,324,086
6,970,684
7,928,694
7,913,253
7,752,163
7,586,935
8,371,712
8,930,309
9,091,088
7,637,625
7,804,136
7,893,996
8,747,370
8,134,463
8,956,610
8,739,004
9,705,970
8,676,222
9,257,211
9,706,563
10,352,738
9,702,517
10,756,982
10,492,962
11,850,590
10,717,147
11,688,432
11,397,329
13,080,936
12,508,385
13,648,881
13,577,575
14,885,183
15,143,121
17,567,734
17,515,241
19,151,625
17,122,313
18,870,658
15,478,585
16,766,779
17,202,514
18,635,656
17,403,428
18,672,091
17,524,640
19,258,134
19,799,482
22,772,559
22,283,780
23,160,572
22,645,427
23,557,817
23,557,81722,645,42723,160,57222,283,78022,772,55919,799,48219,258,13417,524,64018,672,09117,403,42818,635,65617,202,51416,766,77915,478,58518,870,65817,122,31319,151,62517,515,24117,567,73415,143,12114,885,18313,577,57513,648,88112,508,38513,080,93611,397,32911,688,43210,717,14711,850,59010,492,96210,756,9829,702,51710,352,7389,706,5639,257,2118,676,2229,705,9708,739,0048,956,6108,134,4638,747,3707,893,9967,804,1367,637,6259,091,0888,930,3098,371,7127,586,9357,752,1637,913,2537,928,6946,970,6846,324,0866,172,3416,117,3245,676,2845,282,8325,510,3484,810,1684,291,6224,628,1334,504,8364,324,3894,180,3954,097,7903,974,3633,224,2712,925,9302,948,4742,893,4872,883,9452,671,5222,756,8062,647,3632,604,8192,516,5332,297,3312,198,8341,974,6742,012,7601,868,2691,806,3791,376,6731,302,551930,686866,225829,680696,208750,460714,940697,549
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,835,000
5,238,511
5,772,860
3,160,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000003,160,0005,772,8605,238,5113,835,000000000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,835,000
5,238,511
5,772,860
3,160,000
5,917,000
4,617,000
5,250,000
5,110,000
6,010,000
4,017,200
3,947,200
3,668,851
3,370,965
3,888,541
3,403,641
1,804,552
4,572,036
4,300,627
3,696,195
3,696,1954,300,6274,572,0361,804,5523,403,6413,888,5413,370,9653,668,8513,947,2004,017,2006,010,0005,110,0005,250,0004,617,0005,917,0003,160,0005,772,8605,238,5113,835,000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
238,185
240,746
302,230
296,593
396,603
424,785
432,661
576,775
606,207
785,102
872,783
925,917
992,149
1,027,918
1,120,418
1,319,279
1,357,456
1,493,226
1,606,972
1,467,041
1,768,203
1,636,452
1,678,604
1,748,781
2,025,011
2,505,196
2,688,640
2,644,905
2,750,958
2,634,959
2,816,730
2,469,922
2,877,927
3,494,010
3,182,386
3,213,689
3,469,912
3,740,998
3,833,601
4,361,371
5,282,858
5,157,351
4,784,283
4,309,193
5,269,086
4,913,390
5,281,260
4,353,743
4,194,059
4,048,493
3,922,303
3,690,092
4,320,131
4,548,050
5,625,305
4,623,552
4,426,823
4,603,902
5,278,927
4,686,643
5,018,317
4,920,562
5,471,341
5,130,463
4,859,775
4,723,092
5,668,730
5,651,403
5,951,191
6,010,822
6,540,262
6,550,046
7,228,261
7,328,810
7,864,560
7,592,856
6,478,740
6,523,921
7,108,007
7,633,677
7,609,213
7,652,765
7,457,703
8,064,121
8,375,905
8,073,675
8,950,602
10,130,916
9,320,435
9,738,020
9,523,195
9,523,1959,738,0209,320,43510,130,9168,950,6028,073,6758,375,9058,064,1217,457,7037,652,7657,609,2137,633,6777,108,0076,523,9216,478,7407,592,8567,864,5607,328,8107,228,2616,550,0466,540,2626,010,8225,951,1915,651,4035,668,7304,723,0924,859,7755,130,4635,471,3414,920,5625,018,3174,686,6435,278,9274,603,9024,426,8234,623,5525,625,3054,548,0504,320,1313,690,0923,922,3034,048,4934,194,0594,353,7435,281,2604,913,3905,269,0864,309,1934,784,2835,157,3515,282,8584,361,3713,833,6013,740,9983,469,9123,213,6893,182,3863,494,0102,877,9272,469,9222,816,7302,634,9592,750,9582,644,9052,688,6402,505,1962,025,0111,748,7811,678,6041,636,4521,768,2031,467,0411,606,9721,493,2261,357,4561,319,2791,120,4181,027,918992,149925,917872,783785,102606,207576,775432,661424,785396,603296,593302,230240,746238,185
       Other Current Liabilities 
104,398
147,323
145,359
113,640
137,877
148,640
148,515
275,226
242,536
334,387
311,736
268,593
263,625
262,466
264,713
272,864
313,168
248,682
265,119
281,591
257,952
289,645
344,580
269,459
195,370
396,357
346,740
446,267
423,163
561,215
469,872
477,888
446,230
475,878
401,471
607,470
599,142
531,790
467,684
430,836
375,636
489,355
540,808
709,095
506,324
1,015,393
1,009,390
1,095,383
1,164,680
809,751
1,599,526
1,166,526
1,240,503
934,749
1,059,914
512,633
1,352,368
634,541
732,098
613,373
908,315
693,922
1,148,812
772,289
1,873,893
813,753
2,007,166
1,194,927
2,423,690
832,096
1,516,997
1,257,049
3,091,510
1,462,132
2,443,415
1,206,208
2,269,859
1,138,202
3,227,466
1,610,552
4,187,018
1,524,942
3,859,834
1,966,943
6,167,140
1,789,350
4,217,969
4,770,108
4,026,491
3,435,738
4,670,963
4,670,9633,435,7384,026,4914,770,1084,217,9691,789,3506,167,1401,966,9433,859,8341,524,9424,187,0181,610,5523,227,4661,138,2022,269,8591,206,2082,443,4151,462,1323,091,5101,257,0491,516,997832,0962,423,6901,194,9272,007,166813,7531,873,893772,2891,148,812693,922908,315613,373732,098634,5411,352,368512,6331,059,914934,7491,240,5031,166,5261,599,526809,7511,164,6801,095,3831,009,3901,015,393506,324709,095540,808489,355375,636430,836467,684531,790599,142607,470401,471475,878446,230477,888469,872561,215423,163446,267346,740396,357195,370269,459344,580289,645257,952281,591265,119248,682313,168272,864264,713262,466263,625268,593311,736334,387242,536275,226148,515148,640137,877113,640145,359147,323104,398
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
331,940
276,237
289,095
323,261
766,092
1,360,943
1,355,935
1,386,928
2,130,359
3,094,385
3,140,807
3,127,308
2,473,463
1,533,905
1,811,035
2,672,293
2,793,506
3,784,543
2,578,498
2,578,4983,784,5432,793,5062,672,2931,811,0351,533,9052,473,4633,127,3083,140,8073,094,3852,130,3591,386,9281,355,9351,360,943766,092323,261289,095276,237331,940000000000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,835,000
-5,238,511
-5,772,860
-3,160,000
0
0
0
0
145,223
157,785
152,672
124,397
115,863
109,006
122,968
103,233
134,426
129,639
121,694
121,694129,639134,426103,233122,968109,006115,863124,397152,672157,785145,2230000-3,160,000-5,772,860-5,238,511-3,835,000000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
401,517
998,920
7,708
0
2,514
0
0
0
0
0
0
0
0
0
0
00000000002,51407,708998,920401,5170000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
105,263
103,985
100,745
99,242
102,686
47,252
50,531
47,290
47,183
46,446
52,762
42,313
40,270
33,944
34,245
33,965
30,917
32,284
36,892
0
44,862
0
044,862036,89232,28430,91733,96534,24533,94440,27042,31352,76246,44647,18347,29050,53147,252102,68699,242100,745103,985105,263000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
457,864
456,513
446,861
434,434
445,182
447,298
453,165
436,905
444,523
453,412
457,519
465,230
470,226
475,239
465,555
452,863
458,139
458,831
463,785
469,279
474,028
465,014
464,506
464,929
478,311
497,307
492,518
504,595
513,976
509,702
514,517
483,851
494,584
512,493
523,362
555,299
559,701
1,022,677
1,031,532
1,002,982
1,006,182
1,004,671
988,609
939,301
930,281
901,414
954,529
999,110
994,877
1,007,654
1,011,823
1,014,670
993,258
1,008,882
1,034,151
2,141,221
2,190,517
2,224,533
2,265,106
2,301,165
2,350,356
2,361,482
2,413,845
2,626,181
2,686,476
2,698,653
2,709,118
2,777,721
3,762,533
3,797,795
3,830,572
3,669,168
3,726,672
3,754,734
3,890,242
4,013,573
4,125,091
4,095,994
4,208,843
4,257,543
4,325,523
4,320,675
4,438,255
4,606,309
5,699,376
5,742,247
5,857,882
5,999,859
6,170,236
6,160,295
6,291,890
6,291,8906,160,2956,170,2365,999,8595,857,8825,742,2475,699,3764,606,3094,438,2554,320,6754,325,5234,257,5434,208,8434,095,9944,125,0914,013,5733,890,2423,754,7343,726,6723,669,1683,830,5723,797,7953,762,5332,777,7212,709,1182,698,6532,686,4762,626,1812,413,8452,361,4822,350,3562,301,1652,265,1062,224,5332,190,5172,141,2211,034,1511,008,882993,2581,014,6701,011,8231,007,654994,877999,110954,529901,414930,281939,301988,6091,004,6711,006,1821,002,9821,031,5321,022,677559,701555,299523,362512,493494,584483,851514,517509,702513,976504,595492,518497,307478,311464,929464,506465,014474,028469,279463,785458,831458,139452,863465,555475,239470,226465,230457,519453,412444,523436,905453,165447,298445,182434,434446,861456,513457,864
   Common Stock
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
194,261
250,767
250,767
250,767
250,767
250,767
250,767
250,767
250,767
250,767
250,767
250,767
300,920
300,920
300,920
300,920
346,790
346,790
346,790
346,790
346,790
693,581
693,581
693,581
693,581
693,581
693,581
693,581
693,581
693,581
693,581
693,581
693,581
693,581
897,426
897,426
897,426
897,426
897,426
897,426
897,426
897,426
897,426
897,426
897,426
897,426
897,426
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,041,611
1,308,821
1,308,821
1,308,821
0
0
1,310,315
0
01,310,315001,308,8211,308,8211,308,8211,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,6111,041,611897,426897,426897,426897,426897,426897,426897,426897,426897,426897,426897,426897,426897,426693,581693,581693,581693,581693,581693,581693,581693,581693,581693,581693,581693,581693,581346,790346,790346,790346,790346,790300,920300,920300,920300,920250,767250,767250,767250,767250,767250,767250,767250,767250,767250,767250,767194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261194,261
   Retained Earnings 
28,188
10,447
2,959
10,987
21,735
23,852
29,718
6,250
13,868
22,757
26,864
20,225
25,221
31,689
22,267
9,437
14,739
15,541
20,723
22,493
27,840
18,887
22,868
25,273
26,004
38,683
38,482
71,624
81,856
79,499
91,648
77,877
88,116
83,818
95,869
97,360
108,627
124,627
133,995
108,574
114,601
110,511
95,935
0
0
0
0
0
0
0
0
0
40,735
56,191
81,421
159,278
207,527
239,813
280,794
316,002
365,554
379,456
426,830
478,326
538,226
550,309
611,572
677,213
743,486
722,266
780,950
863,299
712,804
806,186
940,794
1,112,545
1,188,504
1,181,079
1,291,064
1,387,725
1,489,681
1,495,506
1,619,474
1,778,330
1,910,884
1,954,490
2,091,537
1,979,703
2,128,860
2,342,295
2,236,576
2,236,5762,342,2952,128,8601,979,7032,091,5371,954,4901,910,8841,778,3301,619,4741,495,5061,489,6811,387,7251,291,0641,181,0791,188,5041,112,545940,794806,186712,804863,299780,950722,266743,486677,213611,572550,309538,226478,326426,830379,456365,554316,002280,794239,813207,527159,27881,42156,19140,73500000000095,935110,511114,601108,574133,995124,627108,62797,36095,86983,81888,11677,87791,64879,49981,85671,62438,48238,68326,00425,27322,86818,88727,84022,49320,72315,54114,7399,43722,26731,68925,22120,22526,86422,75713,8686,25029,71823,85221,73510,9872,95910,44728,188
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135,859
109,952
102,931
192,402
126,435
126,838
197,593
243,371
221,699
224,563
176,603
142,627
131,953
125,565
134,763
103,965
378,906
74,614
369,186
0
386,793
0
0386,7930369,18674,614378,906103,965134,763125,565131,953142,627176,603224,563221,699243,371197,593126,838126,435192,402102,931109,952135,859000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue53,332,176
Cost of Revenue-49,969,547
Gross Profit3,362,6293,362,629
 
Operating Income (+$)
Gross Profit3,362,629
Operating Expense-51,769,634
Operating Income1,562,542-48,407,006
 
Operating Expense (+$)
Research Development34,056
Selling General Administrative1,296,084
Selling And Marketing Expenses-
Operating Expense51,769,6341,330,140
 
Net Interest Income (+$)
Interest Income13,882
Interest Expense-369,928
Other Finance Cost-163,379
Net Interest Income-519,424
 
Pretax Income (+$)
Operating Income1,562,542
Net Interest Income-519,424
Other Non-Operating Income Expenses-
Income Before Tax (EBT)955,9031,562,542
EBIT - interestExpense = -369,928
565,724
935,652
Interest Expense369,928
Earnings Before Interest and Taxes (EBIT)-1,325,830
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax955,903
Tax Provision-262,624
Net Income From Continuing Ops693,279693,279
Net Income565,724
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-519,424
 

Technical Analysis of NanJing Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of NanJing Pharmaceutical Co Ltd. The general trend of NanJing Pharmaceutical Co Ltd is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine NanJing Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NanJing Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 4.65 < 4.65 < 4.71.

The bearish price targets are: 4.4 > 4.38 > 4.38.

Tweet this
NanJing Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NanJing Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NanJing Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NanJing Pharmaceutical Co Ltd. The current macd is 0.00603242.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the NanJing Pharmaceutical Co Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for NanJing Pharmaceutical Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the NanJing Pharmaceutical Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
NanJing Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartNanJing Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NanJing Pharmaceutical Co Ltd. The current adx is 14.19.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell NanJing Pharmaceutical Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
NanJing Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NanJing Pharmaceutical Co Ltd. The current sar is 4.6275488.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NanJing Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NanJing Pharmaceutical Co Ltd. The current rsi is 47.25. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
NanJing Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartNanJing Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NanJing Pharmaceutical Co Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the NanJing Pharmaceutical Co Ltd price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
NanJing Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartNanJing Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NanJing Pharmaceutical Co Ltd. The current cci is -50.8255934.

NanJing Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartNanJing Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NanJing Pharmaceutical Co Ltd. The current cmo is -10.46506933.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NanJing Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartNanJing Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NanJing Pharmaceutical Co Ltd. The current willr is -77.27272727.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that NanJing Pharmaceutical Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NanJing Pharmaceutical Co Ltd Daily Williams %R ChartNanJing Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NanJing Pharmaceutical Co Ltd.

NanJing Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NanJing Pharmaceutical Co Ltd. The current atr is 0.09640028.

NanJing Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartNanJing Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NanJing Pharmaceutical Co Ltd. The current obv is 818,235,751.

NanJing Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartNanJing Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NanJing Pharmaceutical Co Ltd. The current mfi is 66.46.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
NanJing Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartNanJing Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NanJing Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

NanJing Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NanJing Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.245
Ma 20Greater thanMa 504.512
Ma 50Greater thanMa 1004.488
Ma 100Greater thanMa 2004.759
OpenGreater thanClose4.440
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of NanJing Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on NanJing Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about NanJing Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NanJing Pharmaceutical Co Ltd

I send you an email if I find something interesting about NanJing Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about NanJing Pharmaceutical Co Ltd.

Receive notifications about NanJing Pharmaceutical Co Ltd in your mailbox!